Gerresheimer shines: Sales plus thanks to Bormioli Pharma in the first quarter!
Gerresheimer shines: Sales plus thanks to Bormioli Pharma in the first quarter!
Gerresheimer, Deutschland - Gerresheimer AG achieved a significant increase in sales of 11.6 % compared to the previous year in the first quarter of 2025. The turnover is now 520.1 million euros compared to 466.1 million euros in Q1 2024. According to
The company's Adjusted Ebitda margin is 17.6 % in the first quarter, compared to 17.4 % in the previous year. For the year 2025, Gerresheimer expects organic sales growth of 3-5 % and an Adjusted Ebitda margin of around 22 %. The integration of the Bormioli Pharma, which will be fully consolidated from 2025 in December 2024, plays a central role in this. Dietmar Siemssen, CEO of Gerresheimer AG, emphasized that despite temporary market effects in 2024, the long -term growth perspectives remain positive. The Plastics & Devices division generated sales of 294.5 million euros in the first quarter of 2025, which corresponds to an increase of 14.0 % compared to the previous year. However, the organic sales declines in this area amount to 3.3 %, such as supplemented. sales in the Primary Packaging Glass area also rose from 208.4 million euros in the previous year to EUR 227.1 million, with organic a decrease of 10.2 %. However, the adjusted EBITDA in this area rose by 15.4 % to 40.2 million euros, which increased Adjusted Ebitda margin to 17.7 %. These developments are not only due to the acquisition of Bormioli Pharma, but also to the ongoing demand for tailor -made solutions for biopharmaceuticals. In 2024, Gerresheimer already had organic sales growth of 8.0 % in the Plastics & Devices division and an adjusted EBITDA of 293.7 million euros. The turnover in this area was 1,141.3 million euros, while the primary packaging glass business developed stably at 898.6 million euros. The company's medium-term forecast includes organic sales growth of 8-10 % as well as an Adjusted Ebitda margin of 23-25 % and an adapted EPS growth of over 10 % CAGR.
The overall picture is rounded off by the proposed dividend of 1.25 euros per share, which corresponds to a distribution rate of 26.0 %. With the comprehensive integration of Bormioli Pharma and the adaptation to the market changes, Gerresheimer relies on a robust foundation for future growth. forecast and market conditions
long -term perspectives
| Details | |
|---|---|
| Ort | Gerresheimer, Deutschland |
| Quellen | |
Kommentare (0)